EG 427
- Country
- 🇫🇷France
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.eg427.com
Clinical Trials
1
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults With Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
- Conditions
- Neurogenic Detrusor OveractivitySpinal Cord Injuries
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- EG 427
- Target Recruit Count
- 16
- Registration Number
- NCT06596291
- Locations
- 🇺🇸
Rancho Los Amigos National Rehabilitation Center, Downey, California, United States
🇺🇸University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Sidney Kimmel Medical College, Philadelphia, Pennsylvania, United States
News
EG 427 Showcases Breakthrough Dual-Transgene HSV-1 Vector Technology at ASGCT Meeting
EG 427's innovative non-replicative HSV-1 vector technology enables delivery of two transgenes with independent expression kinetics in a single vector, offering significant advantages over current gene therapy approaches.
First-in-Human Trial Tests Herpes Virus-Based Gene Therapy for Neurogenic Bladder in Spinal Cord Injury Patients
A phase 1b/2a clinical trial has begun testing EG110A, a modified herpes virus vector that delivers botulinum toxin genes to treat neurogenic bladder in spinal cord injury patients.
EG 427 Secures €27M Series B to Advance Novel Gene Therapy for Spinal Cord Injury-Related Bladder Dysfunction
• French biotech EG 427 has raised €27M in Series B funding led by Andera Partners and Bpifrance to advance its lead candidate EG110A into Phase Ib/IIa trials for neurogenic detrusor overactivity. • EG110A, utilizing a non-replicating HSV-1 vector, demonstrated promising preclinical results comparable to botulinum toxin A, without the common side effect of increased post-void residual urine volume. • The first-in-human trial will evaluate EG110A in spinal cord injury patients with NDO across four US sites, with an initial 12-month follow-up period and potential 5-year extension for responders.